Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 25

Sort by

Sort Order Select

Journal Articles

Prevention and Management of Daratumumab Mediated Infusion Related Hypersensitivity Reactions Pre-and Post-Implementation of Rapid Infusion Protocol

My L Nguyen, PharmD, Catherine Burdalski, PharmD, BCOP, Syed Abbas Ali, MD, Lindsay Kohler, BS, PharmD Candidate, Steven Gilmore, PharmD, BCOP

Blood (2019) 134 (Supplement_1): 5811.

https://doi.org/10.1182/blood-2019-125391

Published: 2019

Journal Articles

Effect of Cyclosporine Inhalation Solution (CIS) on Lung Function and Inflammatory Biomarkers in Patients with Hematopoietic Stem Cell Transplant (HSCT) Associated Bronchiolitis Obliterans Syndrome (BOS)

Janhavi Athale, MD, Nicole J Gormley, MD, Robert Reger, MS, Sara Alsaaty, MS, Debra Reda, BSN, Tatyana Worthy, MSN, Ankit Saxena, Ph. D, Xin Tian, Ph. D, Richard W. Childs, MD, Anthony F Suffredini, MD

Blood (2019) 134 (Supplement_1): 4552.

https://doi.org/10.1182/blood-2019-122966

Published: 2019

Journal Articles

A Phase Ib Study of Isatuximab in Combination with Bortezomib, Cyclophosphamide, and Dexamethasone (VCDI) in Patients with Newly Diagnosed Multiple Myeloma Non-Eligible for Transplantation

Enrique M. Ocio, MDPhD, Sara Bringhen, MD, Stefania Oliva, MD, Paula Rodriguez-Otero, MD PhD, Dheepak Kanagavel, MD PhD, Corina Oprea, MD, Vivian Wei, Severine Doroumian, Joaquin Martinez-Lopez, MD PhD

Blood (2017) 130 (Supplement 1): 3160.

https://doi.org/10.1182/blood.V130.Suppl_1.3160.3160

Published: 2017

Journal Articles

Monoclonal Antibody Utilization Characteritics in Patients with Multiple Myeloma

Sikander Ailawadhi, Abdel-Ghani Azzouqa, Zahara Meghji, Tania Jain, MD, Nancy Diehl, Stephanie P. Gebhardt, Vishal Shah, David O. Hodge, MS, Raj Patel, MD, Prachi Jani, MD, Taimur Sher, MD, Vivek Roy, MD, Meghna Ailawadhi, MD, Victoria R. Alegria, Aneel Paulus, MD, Asher A. Chanan-Khan, MD, Rafael Fonseca, MD

Blood (2017) 130 (Supplement 1): 5440.

https://doi.org/10.1182/blood.V130.Suppl_1.5440.5440

Published: 2017

Journal Articles

Results of an Interim Safety Analysis of a Phase 2 Study of Daratumumab (Dara) Plus Cyclophosphamide, Bortezomib, and Dexamethasone (CyBorD) in Previously Untreated and Relapsed Patients (Pts) with Multiple Myeloma (MM)

Habte Yimer, MD, Jason Melear, MD, Edward Faber, William I. Bensinger, MD, John M Burke, MD, Sriya Gunawardena, MD, Murphy Sean, Hollee Parros, Yana Lutska, Mohamed Darif, PhD, Anil Londhe, PhD, Ming Qi, Jon Ukropec, Thomas Lin, Robert M. Rifkin, MD

Blood (2017) 130 (Supplement 1): 1839.

https://doi.org/10.1182/blood.V130.Suppl_1.1839.1839

Published: 2017

Journal Articles

Daratumumab Is an Effective and Safe Salvage Therapy in Relapsed/Refractory Patients with Multiple Myeloma after Allogeneic Stem Cell Transplantation

Evgeny Klyuchnikov, MD, Ute-Marie von Pein, MD, Francis A. Ayuk, MD, Maximilian Christopeit, MD, Raissa Adjalle, MD, Andre van Randenborgh, MD, Christine Wolschke, MD, Nicolaus Kröger

Blood (2016) 128 (22): 3437.

https://doi.org/10.1182/blood.V128.22.3437.3437

Published: 2016

Journal Articles

A Prospective Study of IV Pentamidine for Pneumocystis Jirovecii Pneumonia Prophylaxis in Adult Patients with Hematologic Malignancies Undergoing Hematopoietic Stem Cell Transplant or Chemotherapy

Jennifer Anderson, PharmD, Scott Wirth, PharmD, Pritesh R. Patel, MD, John G. Quigley, MD, Annie L. Oh, MD, Christina Mactal-Haaf, PharmD, Irum Khan, MD, Damiano Rondelli, MD, Karen Sweiss, PharmD

Blood (2016) 128 (22): 2207.

https://doi.org/10.1182/blood.V128.22.2207.2207

Published: 2016

Journal Articles

Expanded Phase 1 Study of ABL001, a Potent, Allosteric Inhibitor of BCR-ABL, Reveals Significant and Durable Responses in Patients with CML-Chronic Phase with Failure of Prior TKI Therapy

Blood (2016) 128 (22): 625.

https://doi.org/10.1182/blood.V128.22.625.625

Published: 2016

Journal Articles

Rapid Achievement of MR 4.5 after Switching from Imatinib (IM) to Nilotinib (NIL) in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Preliminary Results from ENESTgoal

Ellen K. Ritchie, MD, Rosalind Catchatourian, MD, Rebecca B. Klisovic, MD, Michael W Deininger, MD PhD, Harry P. Erba, MD PhD, Jerald P. Radich, Michael R. Savona, MD, Ghulam Warsi, PhD, Carole S. Paley, Ilva Dautaj, Felice P. Lin, PharmD, Michael J. Mauro, MD

Blood (2015) 126 (23): 4050.

https://doi.org/10.1182/blood.V126.23.4050.4050

Published: 2015

Journal Articles

Management of Infusion-Related Reactions Following Daratumumab Monotherapy in Patients with at Least 3 Lines of Prior Therapy or Double Refractory Multiple Myeloma (MM): 54767414MMY2002 (Sirius)

Peter M. Voorhees, Brendan Weiss, Saad Usmani, Huaibao Feng, Clarissa Uhlar, Imran Khan, Tahamtan Ahmadi, Sagar Lonial, MD

Blood (2015) 126 (23): 1829.

https://doi.org/10.1182/blood.V126.23.1829.1829

Published: 2015

Journal Articles

An Open-Label, Multicenter, Phase 1b Study of Daratumumab in Combination with Backbone Regimens in Patients with Multiple Myeloma

Philippe Moreau, MD, Maria-Victoria Mateos, Joan Bladé, MD PhD, Lotfi Benboubker, MD PhD, Javier de la Rubia, MD PhD, Thierry Facon, MD, Raymond L. Comenzo, MD, Joseph W. Fay, MD, Xiang Qin, MS, Tara Masterson, MS, Jordan Schecter, MD, Tahamtan Ahmadi, MD, Jesus San Miguel, MD PhD

Blood (2014) 124 (21): 176.

https://doi.org/10.1182/blood.V124.21.176.176

Published: 2014

Journal Articles

Phase II Study Of Anti-CD19 Antibody Drug Conjugate (SAR3419) In Combination With Rituximab: Clinical Activity and Safety In Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (NCT01470456)

Bertrand Coiffier, MD, PhD, Catherine Thieblemont, MD, PhD, Sophie de Guibert, MD, Jehan Dupuis, MD, Vincent Ribrag, Réda Bouabdallah, MD, Franck Morschhauser, MD, PhD, Guillaume Cartron, MD, PhD, Steven Le Gouill, MD, PhD, Olivier Casasnovas, MD, Harald Holte, MD, PhD, Laurence Hatteville, Chiara Zilocchi, Corina Oprea, MD, Hervé Tilly, MD, PhD

Blood (2013) 122 (21): 4395.

https://doi.org/10.1182/blood.V122.21.4395.4395

Published: 2013

Journal Articles

Inhaled Cyclosporine For The Treatment Of Bronchiolitis Obliterans Following Hematopoietic Stem Cell Transplantation (HSCT) Or Lung Transplantation

Nicole Gormley, MD, Catalina Ramos, RN, BSN, Robert Reger, Margaret Tropea, Xin Tian, PhD, Elena Cho, RN, MSN, Debra Reda, RN, Michael Terrin, MD, Leigh Samsel, MS, Millie Whatley, James Shelhamer, MD, Clara C. Chen, MD, Minoo Battiwalla, MD, MS, A. John Barrett, Tim Corcoran, PhD, Aldo Iacono, MD, J. Philip McCoy, PhD, Anthony Suffredini, MD, Richard W. Childs, MD

Blood (2013) 122 (21): 2057.

https://doi.org/10.1182/blood.V122.21.2057.2057

Published: 2013

Journal Articles

Immunochemotherapy As Induction (R-CHOP and R-HyperC-VAD/R-MA) in Mantle Cell Lymphoma, a Hungarian Multicenter Open Label Phase II Study (Rituximab [MabThera®] in Mantle Cell Lymphoma, REMENY)

Miklos Udvardy, MD, PhD, Andras Rosta, MD, PhD, Zoltan Gasztonyi, MD, Zita Borbenyi, MD, PhD, Gaspar Radvanyi, MD, Miklos Egyed, MD, PhD, Beata Gasztonyi, MD, PhD, Hajna Losonczy, MD, PhD, Andras Matolcsy, MD, PhD, Agnes H. Andrasfalvy, MD, Tamas J. Schneider, MD

Blood (2012) 120 (21): 4889.

https://doi.org/10.1182/blood.V120.21.4889.4889

Published: 2012

Journal Articles

Final Results of a Single Arm Phase III Multicenter, Open-Label Study of Rituximab Administered by Faster Infusion in Patients with Previously Untreated Diffuse Large-B Cell (DLBCL) or Follicular Non-Hodgkin's Lymphoma (FL)

Shaker R. Dakhil, MD, Robert Hermann, MD, Akiko Chai, MS, Deborah Hurst, MD, Gregg Fine, MD, Paul Richards, MD

Blood (2011) 118 (21): 2703.

https://doi.org/10.1182/blood.V118.21.2703.2703

Published: 2011

Journal Articles

Iron Dextran Versus Iron Sucrose for Non-Hemodialysis Adult Outpatients with Iron Deficiency Anemia: Assessment of Safety and Feasibility for A Randomized Controlled Trial

Martha L Louzada, BSc, MD, MSc, Cyrus C. Hsia, BSc, MD, FRCPC, Fiona Ralley, MB ChB FRCA, Janet Martin, PharmD, MSc (HTA&M), Sarah Connelly, BSc MSc, Donna Berta, RN, Valerie Binns, RN, George D Ormond, BSc, Ian H. Chin-Yee, MD, FRCPC

Blood (2011) 118 (21): 2107.

https://doi.org/10.1182/blood.V118.21.2107.2107

Published: 2011

Journal Articles

A Phase I/II, Dose-Escalation Study of Daratumumab, A CD38 Mab in Patients with Multiple Myeloma – Preliminary Safety Data

Peter Gimsing, MD, DMSci, Assoc. Prof., Torben Plesner, MD, Hareth Nahi, Henk Lokhorst, MD, PhD, Marie-Louise Valentin, MD, Steen Lisby, MD, DMSc, Paul G. Richardson, MD

Blood (2011) 118 (21): 1873.

https://doi.org/10.1182/blood.V118.21.1873.1873

Published: 2011

Journal Articles

Type 3 Von Willebrand Disease with Alloantibodies and Its Challenging Management During Episode of Bleeding

Anupam Verma, MD, Hassan Yaish, MD, George M. Rodgers, MD, PhD

Blood (2010) 116 (21): 1405.

https://doi.org/10.1182/blood.V116.21.1405.1405

Published: 2010

Journal Articles

Phase I/II Study of IPH1101, γσ T Cell Agonist, Combined with Rituximab, in Low Grade Follicular Lymphoma Patients.

Guy Laurent, MD, PhD, Sylvie Lafaye de Micheaux, MD, Philippe Solal-Celigny, MD, Pierre Soubeyran, MD, PhD, Vincent Delwail, Hervé Ghesquières, MD, Catherine Thieblemont, MD, Eric Jourdan, MD, PhD, Lucile Beautier, Fabien Audibert, Patrick Squiban, MD, Helene Sicard, PhD, Jean-Francois Rossi, MD, PhD

Blood (2009) 114 (22): 1649.

https://doi.org/10.1182/blood.V114.22.1649.1649

Published: 2009

Journal Articles

A Phase I Study of PRO131921, a Novel Anti-CD20 Monoclonal Antibody in Patients with Relapsed/Refractory CD20 + Indolent NHL: Correlation Between Clinical Responses and AUC Pharmacokinetics.

Jonathan W. Friedberg, MD, Julie M. Vose, M.D., Brad S Kahl, MD, Mark W. Brunvand, MD, Andre Goy, MD, Yvette L. Kasamon, Bart Burington, Ph.D, Jing Li, PhD, William Ho, MD, PhD, Bruce D. Cheson, MD

Blood (2009) 114 (22): 3742.

https://doi.org/10.1182/blood.V114.22.3742.3742

Published: 2009

NARROW

Prevention and Management of Daratumumab Mediated Infusion Related Hypersensitivity Reactions Pre-and Post-Implementation of Rapid Infusion Protocol

Effect of Cyclosporine Inhalation Solution (CIS) on Lung Function and Inflammatory Biomarkers in Patients with Hematopoietic Stem Cell Transplant (HSCT) Associated Bronchiolitis Obliterans Syndrome (BOS)

A Phase Ib Study of Isatuximab in Combination with Bortezomib, Cyclophosphamide, and Dexamethasone (VCDI) in Patients with Newly Diagnosed Multiple Myeloma Non-Eligible for Transplantation

Monoclonal Antibody Utilization Characteritics in Patients with Multiple Myeloma

Results of an Interim Safety Analysis of a Phase 2 Study of Daratumumab (Dara) Plus Cyclophosphamide, Bortezomib, and Dexamethasone (CyBorD) in Previously Untreated and Relapsed Patients (Pts) with Multiple Myeloma (MM)

Daratumumab Is an Effective and Safe Salvage Therapy in Relapsed/Refractory Patients with Multiple Myeloma after Allogeneic Stem Cell Transplantation

A Prospective Study of IV Pentamidine for Pneumocystis Jirovecii Pneumonia Prophylaxis in Adult Patients with Hematologic Malignancies Undergoing Hematopoietic Stem Cell Transplant or Chemotherapy

Expanded Phase 1 Study of ABL001, a Potent, Allosteric Inhibitor of BCR-ABL, Reveals Significant and Durable Responses in Patients with CML-Chronic Phase with Failure of Prior TKI Therapy

Rapid Achievement of MR 4.5 after Switching from Imatinib (IM) to Nilotinib (NIL) in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Preliminary Results from ENESTgoal

Management of Infusion-Related Reactions Following Daratumumab Monotherapy in Patients with at Least 3 Lines of Prior Therapy or Double Refractory Multiple Myeloma (MM): 54767414MMY2002 (Sirius)

An Open-Label, Multicenter, Phase 1b Study of Daratumumab in Combination with Backbone Regimens in Patients with Multiple Myeloma

Phase II Study Of Anti-CD19 Antibody Drug Conjugate (SAR3419) In Combination With Rituximab: Clinical Activity and Safety In Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (NCT01470456)

Inhaled Cyclosporine For The Treatment Of Bronchiolitis Obliterans Following Hematopoietic Stem Cell Transplantation (HSCT) Or Lung Transplantation

Immunochemotherapy As Induction (R-CHOP and R-HyperC-VAD/R-MA) in Mantle Cell Lymphoma, a Hungarian Multicenter Open Label Phase II Study (Rituximab [MabThera®] in Mantle Cell Lymphoma, REMENY)

Final Results of a Single Arm Phase III Multicenter, Open-Label Study of Rituximab Administered by Faster Infusion in Patients with Previously Untreated Diffuse Large-B Cell (DLBCL) or Follicular Non-Hodgkin's Lymphoma (FL)

Iron Dextran Versus Iron Sucrose for Non-Hemodialysis Adult Outpatients with Iron Deficiency Anemia: Assessment of Safety and Feasibility for A Randomized Controlled Trial

A Phase I/II, Dose-Escalation Study of Daratumumab, A CD38 Mab in Patients with Multiple Myeloma – Preliminary Safety Data

Type 3 Von Willebrand Disease with Alloantibodies and Its Challenging Management During Episode of Bleeding

Phase I/II Study of IPH1101, γσ T Cell Agonist, Combined with Rituximab, in Low Grade Follicular Lymphoma Patients.

A Phase I Study of PRO131921, a Novel Anti-CD20 Monoclonal Antibody in Patients with Relapsed/Refractory CD20 + Indolent NHL: Correlation Between Clinical Responses and AUC Pharmacokinetics.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only